News

Telitacicept reduces gMG severity in Phase 2 study

Nearly six months of treatment with RemeGen’s telitacicept (RC18) lessened disease activity in adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor, according to data from a Phase 2 clinical trial in China. “Telitacicept demonstrated safety [and] good tolerability and reduced clinical…

CAR T-cell therapy Descartes-08 receives RMAT status from FDA

Cartesian Therapeutics’ investigational cell therapy Descartes-08 has been granted regenerative medicine advanced therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of myasthenia gravis (MG). RMAT status is intended for experimental regenerative medicines to treat, modify, reverse, or cure a serious or life-threatening…

MG treatment side effects common, especially in women: Survey

Patients, especially women, experience a high degree of side effects from myasthenia gravis (MG) treatment, according to a U.K. survey examining real-world use of the medications. As steroid-sparing agents, mycophenolate mofetil (sold as CellCept) and methotrexate (sold as Trexall, among others) were less likely to be discontinued…

Use of off-label Vyvgart successful in case of hard-to-treat gMG

A woman with hard-to-treat generalized myasthenia gravis (gMG) who was seronegative, or tested negative for disease-driving self-directed antibodies, was successfully treated with off-label Vyvgart (efgartigimod alfa-fcab), as reported in a case study from Italy. According to researchers, this case provides evidence that limiting Vyvgart to MG patients with…

Acupuncture, moxibustion may relieve myasthenia gravis symptoms

A traditional Chinese medicine practice that combines acupuncture and moxibustion, given along with standard treatments, may ease symptoms for people with myasthenia gravis (MG) more effectively than conventional medications alone. That’s according to “Acupuncture and moxibustion treatment for myasthenia gravis: A systematic review and meta-analysis,” which…

Soliris benefits maintained after patients switch to Ultomiris: Study

The initial treatment benefits of Soliris (eculizumab) were maintained after people with generalized myasthenia gravis (gMG) switched over to Ultomiris (ravulizumab-cwvz), a small real-world study confirmed. Most patients who completed a survey almost six months after switching said they preferred Ultomiris due to treatment convenience, lower frequency…

Asthma therapy may help ease symptoms of MuSK-positive MG

Treatment with an oral version of salbutamol, the active ingredient of medications used for asthma and other respiratory conditions, may help ease symptoms in some people with MuSK-positive myasthenia gravis (MG), a small study reports. The study was published as a letter to the editor, titled “…